Comparative Pharmacology
Head-to-head clinical analysis: SODIUM LACTATE IN PLASTIC CONTAINER versus SYNOVALYTE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM LACTATE IN PLASTIC CONTAINER versus SYNOVALYTE IN PLASTIC CONTAINER.
SODIUM LACTATE IN PLASTIC CONTAINER vs SYNOVALYTE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium lactate is converted to bicarbonate in the liver, providing an alkalizing effect to correct metabolic acidosis.
SYNOVALYTE is a hyaluronan preparation that acts as a viscoelastic supplement, restoring the rheological properties of synovial fluid in osteoarthritic joints. It provides lubrication and shock absorption, and may exert anti-inflammatory and analgesic effects through modulation of synovial fluid viscosity and interaction with hyaluronan receptors.
Intravenous (IV) infusion: Initial dose 300-500 mL of 1/6 M (M/6) sodium lactate solution (167 mEq/L of sodium and lactate) infused over 1-2 hours; subsequent doses based on serum bicarbonate levels and clinical response.
Intra-articular injection: 2 mL per joint once weekly for 3 weeks.
None Documented
None Documented
The terminal elimination half-life of lactate is approximately 5–10 minutes due to rapid hepatic metabolism; this short half-life allows quick correction of metabolic acidosis when administered intravenously.
Not applicable; components (sodium, chloride, lactate) are endogenous and rapidly redistributed; lactate half-life ~5-10 minutes in normal hepatic function.
Sodium lactate is metabolized to bicarbonate in the liver via the Cori cycle; less than 5% is excreted unchanged in urine under normal conditions. Biliary/fecal elimination is negligible.
Renal excretion of sodium, chloride, and lactate; not metabolized; elimination routes not quantified as it is a crystalloid solution.
Category C
Category C
Electrolyte Solution
Electrolyte Solution